Холангиоцеллюлярная карцинома сегодня. Литературный аналитический обзор


https://doi.org/10.18027/2224-5057-2015-3-3-17

Полный текст:


Аннотация

Холангиокарцинома (ХГК) представляет собой группу злокачественных опухолей с признаками дифференцировки в направлении эпителия желчных путей. Анатомически ХГК подразделяют на внутрипеченочные, воротные и дистальные. Данные подтипы различаются не только по локализации, но и по эпидемиологии, этиологии, патогенезу и лечению. Частота встречаемости и смертность от ХГК за последние десятилетия существенно выросли, в то время как выживаемость остается низкой. В разных географических областях вариации ХГК обусловлены различными факторами риска. В последние годы накоплены данные по генетическим изменениям клеток ХГК, кроме того обнаружено что строма этой опухоли содержит множество карциномазависимых фибробластов (КЗФ), стимулирующих развитие и рост опухоли. В характеристике и понимании онкогенезавнутрипеченочной ХГК и воротной ХГК отмечается существенный прогресс. Пациентов с внутрипеченочной ХГК обычно лечат хирургически. Для воротной ХГК основным методом лечения является трансплантация печени с неоадъювантной химиотерапией. Предлагаем обзор современного понимания эпидемиологии, патогенеза, классификации, взглядов на диагностику и лечение ХГК


Об авторе

Д. Л. РОТИН
Московский Клинический Научный Центр Департамента Здравоохранения г. Москвы
Россия

д.м.н., заведующий патологоанатомическим отделением



Список литературы

1. Welzel TM, McGlynn KA, Hsing AW et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006; Vol. 98: p. 873–875.

2. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; Vol. 8: p. 512–522.

3. Deoliveira ML, Schulick RD, Nimura Y, et al New staging system and a registry for perihilar cholangiocarcinoma. Hepatology. 2011; Vol. 53: p.1363–1371.

4. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007; Vol. 245: p.755–762.

5. Blechacz BG, GJ. Feldman: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 9. Vol. 1. Saunders; 2010. Tumors of the Bile Ducts, Gallbladder, and Ampulla; pp. 1171–1176.

6. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; Vol.61: p.1657–69.

7. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology. 2009; Vol.136: p.1134– 1144.

8. Tyson GL, El-Serag HB. Risk factors forcholangiocarcinoma. Hepatology. 2011; Vol. 54: p.173–184.

9. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; Vol. 24: p.115–125.

10. Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 2008; Vol. 24: p.349–356.

11. Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; Vol. 37: p.806–813.

12. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008; Vol. 10: p.77–82.

13. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006; Vol. 15: p. 1198–1203.

14. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001; Vol. 33: p.1353–1357.

15. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002; Vol. 2: p.10.

16. Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us? Journal of Hepatology. 2012; Vol. 56: p.848–854.

17. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013; Vol. 11: p.13–21.

18. Shin HR, Oh JK, Lim MK, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010; Vol. 25: p. 1011–1016.

19. Huang MH, Chen CH, Yen CM, et al. Relation of hepatolithiasis to helminthic infestation. J Gastroenterol Hepatol. 2005; Vol.20: p.141–146.

20. Edil BH, Cameron JL, Reddy S, et al. Choledochal cyst disease in children and adults: a 30-year singleinstitution experience. J Am Coll Surg. 2008; Vol. 206: p1000–1005. discussion 1005–8.

21. Mabrut JY, Bozio G, Hubert C, Gigot JF. Management of congenital bile duct cysts. Dig Surg. 2010; Vol. 27: p 12–18.

22. Kato I, Kido C. Increased risk of death in thorotrastexposed patients during the late follow-up period. Jpn J Cancer Res. 1987; vol. 78: p.1187–1192.

23. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008; vol. 103: p.1716–720.

24. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007; Vol. 102: p.1016–1021.

25. Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998; Vol. 28: p.921–925.

26. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; Vol. 57: p. 69–76.

27. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005; Vol.128: p. 620–626.

28. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; Vol. 5: p. 1221–1228.

29. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007; Vol.120: p.638–641.

30. Nakanuma Y, Sato Y, Harada K, et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010; Vol.2: p.419–427.

31. Komuta M, Spee B, Vander Borght S, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology. 2008; Vol.47: p.1544–1556.

32. Tsuchiya A, Kamimura H, Tamura Y, et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. Cancer Lett. 2011; Vol.309: p.95–103.

33. Cardinale V, Carpino G, Reid L, et al. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol. 2012; Vol.4: p. 94–102.

34. Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012; Vol. 55: p.1876–1888.

35. Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; Vol.122: p.2911–2915.

36. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012; Vol.122: p.3914– 3918.

37. Holczbauer A, Factor VM, Andersen JB, et al. Modeling pathogenesis of primary liver cancer in lineagespecific mouse celltypes. Gastroenterology. 2013; Vol. 145: p. 221–231.

38. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000; Vol. 60: p.184–190.

39. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999; Vol.30: p.1128–1133.

40. Kobayashi S, Werneburg NW, Bronk SF, et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 2005; Vol.128: p.2054–2065.

41. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 2004; Vol. 64: p. 3517–3524.

42. Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology. 2005; Vol.42: p.1329–38.

43. Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol. 2006; Vol. 44: p.1055–1065.

44. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013.

45. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; Vol.144: p.829–840.

46. Isomoto H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology. 2007; Vol. 132: p .384–396.

47. Yoon JH, Gwak GY, Lee HS, et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004; Vol. 41: p. 808–814.

48. Kiguchi K, Carbajal S, Chan Ket al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001; Vol.61: p.6971–6976.

49. Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int J Cancer. 2006; Vol. 119: p. 477–483.

50. Nishimura K, Kitamura M, Miura H, et al. Prostate stromal cell-derived hepatocyte growth factor induces invasion of prostate cancer cell line DU145 through tumor-stromal interaction. Prostate. 1999; Vol. 41: p. 145–153.

51. Nakamura T, Matsumoto K, Kiritoshi A, et al. Induction of hepatocyte growth factor in fibroblasts by tumorderived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res. 1997; Vol.57: p.3305–3313.

52. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; Vol. 7: p. 504–516.

53. Lai GH, Radaeva S, Nakamura T, Sirica AE. Unique epithelial cell production of hepatocyte growth factor/scatter factor by putative precancerous intestinal metaplasias and associated “intestinal-type” biliary cancer chemically induced in rat liver. Hepatology. 2000; Vol.31: p.1257–1265.

54. Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011; Vol.105: p.131–138.

55. Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C–MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producingcholangiocarcinoma. Hepatology. 1999; Vol. 29: p.1453–1462.

56. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002; Vol.122: p.985–993.

57. Yoon JH, Canbay AE, Werneburg NW, et al. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis. Hepatology. 2004; Vol.39: p. 732–738.

58. Kuver R. Mechanisms of oxysterol-induced disease: insights from the biliary system. Clin Lipidol. 2012; Vol. 7: p. 537–548.

59. Nachtergaele S, Mydock LK, Krishnan K, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol. 2012; Vol. 8: p. 211– 220.

60. Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011; Vol. 54: p. 2076–2088.

61. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2012; Vol. 28: p.266–272.

62. McKay SC, Unger K, Pericleous S, et al. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) 2011; Vol.13: p.309–319.

63. Koo SH, Ihm CH, Kwon KC, et al. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet. 2001; Vol.130: p.22–28.

64. Uhm KO, Park YN, Lee JY, et al. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2005; Vol.157: p.37–41.

65. Lee JY, Park YN, Uhm KO, et al. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci. 2004; Vol.19: p.682–687.

66. Wong N, Li L, Tsang K, Lai PB, et al. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol. 2002; Vol.37: p. 633–639.

67. Homayounfar K, Gunawan B, Cameron S, et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol. 2009; Vol.40: p. 834–842.

68. Ong CK, Subimerb C, Pairojkul C, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; Vol. 44: p.690–693.

69. Xu RF, Sun JP, Zhang SR, et al. KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 2011; Vol.65: p.22–26.

70. Ohashi K, Nakajima Y, Kanehiro H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995; Vol.109: p.1612–1617.

71. Andersen JB, Spee B, Blechacz BR, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; Vol.142: p.1021–1031.

72. Tada M, Omata M, Ohto M. High incidence of ras gene mutation in intrahepatic cholangiocarcinoma. Cancer. 1992; Vol.69: p.1115–1118.

73. Khan SA, Thomas HC, Toledano MB, et al. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005; Vol.25: p.704–716.

74. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; Vol.43: p.1552–1558.

75. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; Vol.17: p.72–79.

76. Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2012.

77. Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010; Vol. 17: p. 215–216.

78. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; Vol.340: p.626–630.

79. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; Vol.340: p.622–626.

80. Oishi N, Kumar MR, Roessler S, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepaticcholangiocarcinoma. Hepatology. 2012; Vol.56: p.1792–1803.

81. Chen L, Yan HX, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009; Vol. 50: p. 358–369.

82. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer discovery. 2013; Vol.3: p.636–647.

83. Yamanaka S, Olaru AV, An F, et al. MicroRNA-21 inhibits Serpini1, a gene with novel tumour suppressive effects in gastric cancer. Dig Liver Dis. 2012; Vol.44: p.589–596.

84. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; Vol.130: p.2113–2129.

85. Hofmann JJ, Zovein AC, Koh H, et al. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development. 2010; Vol.137: p.4061–4072.

86. Zender S, Nickeleit I, Wuestefeld T, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013; Vol.23: p.784–795.

87. Jinawath A, Akiyama Y, Sripa B, Yuasa Y. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol. 2007; Vol.133: p.271–278.

88. El Khatib M, Kalnytska A, Palagani V, et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology. 2013; Vol.57: p.1035–1045.

89. Sirica AE, Nathanson MH, Gores GJ, Larusso NF. Pathobiology of biliary epithelia and cholangiocarcinoma: proceedings of the Henry M and Lillian Stratton Basic Research Single-TopicConference. Hepatology. 2008; Vol.48: p. 2040–2046.

90. Tanaka S, Sugimachi K, Kameyama T, et al. WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology. 2003; Vol.37: p.1122–1129.

91. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013; Vol.501: p.346–354.

92. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012; Vol. 9: p.44–54.

93. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; Vol.6: p.392–401.

94. Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology. 2010; Vol.51: p.1438–1444.

95. Okabe H, Beppu T, Hayashi H, et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009; Vol.16: p.2555–2564.

96. Quante M, Tu SP, Tomita H, et al. Bone marrowderived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011; Vol.19: p.257–272.

97. Li T, Li D, Cheng L, et al. Epithelial-mesenchymal transition induced by hepatitis C virus core protein in cholangiocarcinoma. Ann Surg Oncol. 2010; Vol. 17: p.1937–1944.

98. Sato Y, Harada K, Itatsu K, et al. Epithelialmesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010; Vol.177: p.141–152.

99. Korita PV, Wakai T, Ajioka Y, et al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 2010; Vol.30: p.2279–2285.

100. Cadamuro M, Nardo G, Indraccolo S, et al. Plateletderived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013

101. Fingas CD, Mertens JC, Razumilava N, et al. Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012; Vol.32: p. 400–409.

102. Utispan K, Thuwajit P, Abiko Y, et al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010; Vol.9: p.13.

103. Baril P, Gangeswaran R, Mahon PC, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3kpathway. Oncogene. 2007; Vol.26: p.2082–2094.

104. Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol. 2010; Vol.16: p.713–722.

105. Ohira S, Sasaki M, Harada K, et al. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol. 2006; Vol.168: p.1155–1168.

106. Leelawat K, Leelawat S, Narong S, Hongeng S. Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol. 2007; Vol.13: p.1561–1568.

107. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology. 1996; Vol. 23: p. 1341–1344.

108. Prakobwong S, Yongvanit P, Hiraku Y, et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010; Vol.127: p.2576–2587.

109. Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008; Vol.37: p.154–158.

110. Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013; Vol. 73: p. 897–907.

111. Ko KS, Peng J, Yang H. Animal models of cholangiocarcinoma. Curr Opin Gastroenterol. 2013; Vol.29: p.312–318.

112. Fava G, Marucci L, Glaser S, et al. gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res. 2005; Vol.65: p.11437–11446.

113. Pawar P, Ma L, Byon CH, et al. Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin Cancer Res. 2009; Vol.15: p. 1288–1296.

114. Tang T, Zheng JW, Chen B, et al. Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int. 2007; Vol.6: p. 303–307.

115. Zhang J, Han C, Wu T. MicroRNA-26a promotes cholangiocarcinoma growth by activating betacatenin. Gastroenterology. 2012; Vol.143: p.246–526.

116. Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 2011; Vol. 54: p.2089–2098.

117. Zhang K, Chen D, Wang X, et al. RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via Upregulating PUMA. Int J Mol Sci. 2011; Vol.12: p.385–400.

118. Obchoei S, Weakley SM, Wongkham S, et al. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer. 2011; Vol.10: p.102.

119. Hou YJ, Dong LW, Tan YX, et al. Inhibition of active autophagy induces apoptosis and increases chemosensitivity in cholangiocarcinoma.Lab Invest.2011; Vol. 91: p.1146–1157.

120. Xu X, Kobayashi S, Qiao W, et al. Induction of intrahepatic cholangiocellular carcinoma by liverspecific disruption of Smad4 and Pten in mice. J Clin Invest. 2006; Vol.116: p.1843–1152.

121. Farazi PA, Zeisberg M, Glickman J, et al. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006; Vol. 66: p. 6622–6627.

122. Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010; Vol.107: p.1431–1436.

123. Lee KP, Lee JH, Kim TS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010; Vol.107: p.8248–8253.

124. O’Dell MR, Huang JL, Whitney-Miller CL, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 2012; Vol.72: p.1557–1567.

125. Sirica AE, Zhang Z, Lai GH, et al. A novel “patientlike” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008; Vol. 47: p.1178–1190.

126. Campbell DJ, Dumur CI, Lamour NF, et al. Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res. 2012; Vol.42: p.1119–1130.

127. Fava G, Alpini G, Rychlicki C, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res. 2008; Vol.68: p.6752–6761.

128. Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011; Vol.141: p.378–388.

129. Plengsuriyakarn T, Eursitthichai V, Labbunruang N, et al. Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/dimethylnitrosamine-induced hamsters. Asian Pac J Cancer Prev. 2012; Vol.13: p.87–90.

130. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003; Vol. 10: p.288–291.

131. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellularcarcinoma. Hepatology. 2009; Vol.50: p.791–798.

132. Vilgrain V. Staging cholangiocarcinoma by imaging studies. HPB (Oxford) 2008; Vol. 10: p.106–109.

133. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; Vol.48: p.308–321.

134. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000; Vol. 95: p. 204–207.

135. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011; Vol.17: p.934–942.

136. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; Vol.248: p.84–96.

137. Choi SB, Kim KS, Choi JY, et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol. 2009; Vol. 16: p.3048–3056.

138. Li YY, Li H, Lv P, et al. Prognostic value of cirrhosis for intrahepatic cholangiocarcinoma after surgical treatment. J Gastrointest Surg. 2011; Vol.15: p.608–613.

139. Fabris L, Cadamuro M, Moserle L, et al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology. 2011; Vol.54: p.890–899.

140. Kuhlmann JB, Blum HE. Locoregional therapy for cholangiocarcinoma. Curr Opin Gastroenterol. 2013; Vol.29: p.324–328.

141. Valle J, Wasan H, Palmer DH, et al. Investigators ABCT. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; Vol.362: p.1273–1281.

142. Yamashita Y, Takahashi M, Kanazawa S, et al. Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography. Acta Radiol. 1992; Vol.33: p.351–355.

143. Heimbach JK, Sanchez W, Rosen CB, Gores GJ. Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination.HPB (Oxford) 2011; Vol.13: p.356–360.

144. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures.Gastroenterology.2006; Vol.131: p.1064–1072.

145. Barr Fritcher EG, Kipp BR, Voss JS, et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma.Am J Gastroenterol.2011; Vol.106:2023–2028.

146. Barr Fritcher EG, Voss JS, Jenkins SM, et al. Primary sclerosing cholangitis with equivocal cytology: Fluorescence in situ hybridization and serum CA 19–9 predict risk of malignancy.Cancer Cytopathol.2013.

147. Nagorney DM, Kendrick ML. Hepatic resection in the treatment of hilar cholangiocarcinoma.Adv Surg.2006; Vol.40: p.159–171.

148. Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.Gastroenterology.2012; Vol.143: p.88–98.

149. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24- year experience in a single center. Arch Surg. 2011; Vol.146: p.683–689.

150. Geynisman DM, Catenacci DV. Toward personalized treatment of advanced biliary tract cancers. Discov Med. 2012; Vol.14: p.41–57.


Дополнительные файлы

Для цитирования: РОТИН Д.Л. Холангиоцеллюлярная карцинома сегодня. Литературный аналитический обзор. Злокачественные опухоли. 2015;(3):3-17. https://doi.org/10.18027/2224-5057-2015-3-3-17

For citation: ROTIN D.L. Cholangiocellular Cholangiocellular carcinoma today. Literature review. Malignant tumours. 2015;(3):3-17. (In Russ.) https://doi.org/10.18027/2224-5057-2015-3-3-17

Просмотров: 567

Обратные ссылки

  • Обратные ссылки не определены.


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)